{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:21:44Z","timestamp":1792570904022,"version":"4.5.0"},"reference-count":57,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100013465","name":"Association Fran\u00e7aise contre les Myopathies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TRANSLAMUSCLE","award":["19507"],"award-info":[{"award-number":["19507"]}]},{"name":"TRANSLAMUSCLE","award":["22946"],"award-info":[{"award-number":["22946"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale pour la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RHU CARMMA","award":["ANR-15-RHUS-0003"],"award-info":[{"award-number":["ANR-15-RHUS-0003"]}]},{"name":"MYOCILINF-2023","award":["ANR AAPG2023"],"award-info":[{"award-number":["ANR AAPG2023"]}]},{"name":"R\u00e9gion Ile-de-France ARDOC Fellowship"},{"name":"Soci\u00e9t\u00e9 Fran\u00e7aise de Myologie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Idiopathic immune myopathies (IIM) represent a heterogeneous group of diseases, in which muscle lesions result from deregulated immune reactions. Typical histological features include myofibre necrosis, leucocyte infiltration and aberrant myofibre major histocompatibility complex (MHC) expression. To investigate the link between MHC expression, inflammation and muscle lesions, muscle biopsies from IIM patients were analysed by transcriptomics. Both anti-synthetase syndrome (ASS) and inclusion body myositis (IBM) displayed the upregulation of interferon-\u03b3 (IFN-\u03b3) and senescence signalling pathways. Notably, IFN-\u03b3 expression significantly correlated with myofibre atrophy in ASS and IBM muscle biopsies. In addition to MHC-II expression at the myofibre sarcolemma in IBM, we observed a marked overexpression in the muscle stem cell (MuSC) population, suggesting that resident satellite cells respond to IFN-\u03b3 in this condition. To examine the link between IFN-\u03b3 and muscle atrophy via MuSCs, we implanted an osmotic pump chronically releasing recombinant mouse IFN-\u03b3 in wild-type mice subjected to acute muscle injury. Under IFN-\u03b3 exposure, post-injury muscle repair was associated with significantly reduced muscle weight and myofibre diameter, while promoting interstitial fibrosis and fat deposition.<\/jats:p>\n               <jats:p>The mechanism of action of the IFN-\u03b3-induced myofibre atrophy was further investigated in vitro using cultured human MuSCs. IFN-\u03b3 stimulation dramatically impaired MuSC proliferation, fusion and promoted cell senescence. Isolated myofibres from IFN-\u03b3-treated wild-type mice displayed a significant decrease of myogenic regulatory factor MyoD expression and cell cycling, suggesting that IFN-\u03b3 also prevents MuSC activation. In vitro, ruxolitinib, a commercially available Janus kinase (JAK)1\/2 antagonist, blocked IFN-\u03b3-induced expression of MHC-II, restored normal MuSC proliferation and reduced \u03b2-galactosidase activity, a marker of cell senescence. In vivo, oral delivery of ruxolitinib improved myofibre size and biomarkers of muscle atrophy.<\/jats:p>\n               <jats:p>Our study provides multiple lines of evidence that IFN-\u03b3 may mediate muscle atrophy in IBM patients. The identified mechanism of action involves JAK1\/2 pathways, which impair MuSC function by preventing post-lesion myogenesis and promoting cell senescence. Our data suggest that repurposing JAK1\/2 inhibitors may offer a new therapeutic option for treating IBM, a condition known for its resistance to classical immunosuppressant drugs, despite their effectiveness in other IIM.<\/jats:p>","DOI":"10.1093\/brain\/awaf153","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T04:11:34Z","timestamp":1745899894000},"page":"2883-2898","source":"Crossref","is-referenced-by-count":14,"title":["Interferon-\u03b3 causes myogenic cell dysfunction and senescence in immune myopathies"],"prefix":"10.1093","volume":"148","author":[{"given":"Cyrielle","family":"Hou","sequence":"first","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baptiste","family":"Periou","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"Reference Centre for Neuromuscular Diseases \u2018Nord-Est-Ile de France\u2019 , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"AP-HP, Henri Mondor University Hospital, Pathology Department , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Gervais","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Martin","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Berthier","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Baba-Amer","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Souvannanorath","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"Reference Centre for Neuromuscular Diseases \u2018Nord-Est-Ile de France\u2019 , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"AP-HP, Henri Mondor University Hospital, Pathology Department , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuele","family":"Lechapt-Zalcman","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"AP-HP, Henri Mondor University Hospital, Pathology Department , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Malfatti","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"Reference Centre for Neuromuscular Diseases \u2018Nord-Est-Ile de France\u2019 , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"AP-HP, Henri Mondor University Hospital, Pathology Department , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain K","family":"Gherardi","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric","family":"Relaix","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilien","family":"Bencze","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0182-2052","authenticated-orcid":false,"given":"Fran\u00e7ois-J\u00e9r\u00f4me","family":"Authier","sequence":"additional","affiliation":[{"name":"IMRB U955-Team Relaix, Paris Est Cr\u00e9teil University, INSERM , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"Reference Centre for Neuromuscular Diseases \u2018Nord-Est-Ile de France\u2019 , Cr\u00e9teil F-94010 ,","place":["France"]},{"name":"AP-HP, Henri Mondor University Hospital, Pathology Department , Cr\u00e9teil F-94010 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2025080112522841700_awaf153-B1","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025080112522841700_awaf153-B2","first-page":"403","article-title":"Performance of the 2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: A scoping review","volume":"42","author":"Saygin","year":"2023","journal-title":"Clin Exp Rheumatol."},{"key":"2025080112522841700_awaf153-B3","doi-asserted-by":"crossref","first-page":"e000811","DOI":"10.1136\/rmdopen-2018-000811","article-title":"Distinct interferon signatures stratify inflammatory and dysimmune myopathies","volume":"5","author":"Rigolet","year":"2019","journal-title":"RMD Open"},{"key":"2025080112522841700_awaf153-B4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.autrev.2019.02.003","article-title":"CD8+ T-bet+ cells as a predominant biomarker for inclusion body myositis","volume":"18","author":"Dzangu\u00e9-Tchoupou","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025080112522841700_awaf153-B5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s40478-014-0154-2","article-title":"Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy","volume":"2","author":"Aouizerate","year":"2014","journal-title":"Acta Neuropathol Commun"},{"key":"2025080112522841700_awaf153-B6","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3233\/JND-180308","article-title":"Current classification and management of inflammatory myopathies","volume":"5","author":"Schmidt","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"2025080112522841700_awaf153-B7","doi-asserted-by":"crossref","first-page":"5069042","DOI":"10.1155\/2018\/5069042","article-title":"Clinical, histological, and immunohistochemical findings in inclusion body myositis","volume":"2018","author":"de Camargo","year":"2018","journal-title":"BioMed Res Int"},{"key":"2025080112522841700_awaf153-B8","doi-asserted-by":"crossref","first-page":"331ra41","DOI":"10.1126\/scitranslmed.aad4583","article-title":"Targeting protein homeostasis in sporadic inclusion body myositis","volume":"8","author":"Ahmed","year":"2016","journal-title":"Sci Transl Med"},{"key":"2025080112522841700_awaf153-B9","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00401-013-1186-6","article-title":"Dysferlin is a newly identified binding partner of A\u03b2PP and it co-aggregates with amyloid-\u03b242 within sporadic inclusion-body myositis (s-IBM) muscle fibers","volume":"126","author":"Cacciottolo","year":"2013","journal-title":"Acta Neuropathol."},{"key":"2025080112522841700_awaf153-B10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s40478-022-01389-6","article-title":"Inclusion body myositis and associated diseases: An argument for shared immune pathologies","volume":"10","author":"Nelke","year":"2022","journal-title":"Acta Neuropathol Commun"},{"key":"2025080112522841700_awaf153-B11","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/BOR.0000000000000653","article-title":"Interferon-signature in idiopathic inflammatory myopathies","volume":"31","author":"Gallay","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"2025080112522841700_awaf153-B12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","article-title":"Interferon-\u03b1\/\u03b2-mediated innate immune mechanisms in dermatomyositis","volume":"57","author":"Greenberg","year":"2005","journal-title":"Ann Neurol"},{"key":"2025080112522841700_awaf153-B13","doi-asserted-by":"crossref","first-page":"e1193","DOI":"10.1212\/WNL.0000000000008128","article-title":"Identification of distinctive interferon gene signatures in different types of myositis","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2025080112522841700_awaf153-B14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0065-2776(07)96002-2","article-title":"Regulation of interferon-\u03b3 during innate and adaptive immune responses","volume":"96","author":"Schoenborn","year":"2007","journal-title":"Adv Immunol."},{"key":"2025080112522841700_awaf153-B15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3 signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"2025080112522841700_awaf153-B16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.8016643","article-title":"Regulation of MHC class 11 expression by interferon-y mediated by the transactivator gene CIITA","volume":"265","author":"Steimle","year":"1994","journal-title":"Sciences."},{"key":"2025080112522841700_awaf153-B17","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1074-7613(00)80468-9","article-title":"Activation of the MHC class II transactivator CIITA by interferon-\u03b3 requires cooperative interaction between stat1 and USF-1","volume":"8","author":"Muhlethaler-Mottet","year":"1998","journal-title":"Immunity"},{"key":"2025080112522841700_awaf153-B18","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1212\/WNL.41.7.1128","article-title":"Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma","volume":"41","author":"Mantegazza","year":"1991","journal-title":"Neurology"},{"key":"2025080112522841700_awaf153-B19","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf118","article-title":"Mitochondrial damage is associated with an early immune response in inclusion body myositis","author":"Kleefeld","year":"7  2025","journal-title":"Brain"},{"key":"2025080112522841700_awaf153-B20","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1038\/s41467-024-49460-1","article-title":"IFN\u03b3 causes mitochondrial dysfunction and oxidative stress in myositis","volume":"15","author":"Abad","year":"2024","journal-title":"Nat Commun"},{"key":"2025080112522841700_awaf153-B21","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1212\/WNL.0000000000000642","article-title":"Evaluation and construction of diagnostic criteria for inclusion body myositis","volume":"83","author":"Lloyd","year":"2014","journal-title":"Neurology"},{"key":"2025080112522841700_awaf153-B22","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: Analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine (Baltimore)"},{"key":"2025080112522841700_awaf153-B23","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13395-019-0200-7","article-title":"Automated image-analysis method for the quantification of fiber morphometry and fiber type population in human skeletal muscle","volume":"9","author":"Reyes-Fernandez","year":"2019","journal-title":"Skelet Muscle"},{"key":"2025080112522841700_awaf153-B24","doi-asserted-by":"crossref","first-page":"8528","DOI":"10.1038\/ncomms9528","article-title":"Numb is required to prevent p53-dependent senescence following skeletal muscle injury","volume":"6","author":"Le Roux","year":"2015","journal-title":"Nat Commun"},{"key":"2025080112522841700_awaf153-B25","doi-asserted-by":"crossref","first-page":"e0147198","DOI":"10.1371\/journal.pone.0147198","article-title":"Comparative study of injury models for studying muscle regeneration in mice","volume":"11","author":"Hardy","year":"2016","journal-title":"PLoS One"},{"key":"2025080112522841700_awaf153-B26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4939-1435-7_6","article-title":"Isolation, culture and immunostaining of skeletal muscle fibres to study myogenic progression in satellite cells","volume":"1210","author":"Moyle","year":"2014","journal-title":"Methods Mol Biol"},{"key":"2025080112522841700_awaf153-B27","first-page":"940","article-title":"Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis","volume":"27","author":"Nyberg","year":"2000","journal-title":"J Rheumatol"},{"key":"2025080112522841700_awaf153-B28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/1381612043453414","article-title":"Endothelial expression of MHC class II molecules in autoimmune disease","volume":"10","author":"Turesson","year":"2004","journal-title":"Curr Pharm Des"},{"key":"2025080112522841700_awaf153-B29","first-page":"2021","article-title":"Clearance and distribution of recombinant murine \u03b3-interferon in mice","volume":"48","author":"Gonias","year":"1988","journal-title":"Cancer Res"},{"key":"2025080112522841700_awaf153-B30","doi-asserted-by":"crossref","first-page":"16139","DOI":"10.1074\/jbc.271.27.16139","article-title":"Heparin decreases the blood clearance of interferon-\u03b3 and increases its activity by limiting the processing of its carboxyl-terminal sequence","volume":"271","author":"Lortat-Jacob","year":"1996","journal-title":"J Biol Chem"},{"key":"2025080112522841700_awaf153-B31","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1083\/jcb.200212046","article-title":"Satellite cells attract monocytes and use macrophages as a support to escape apoptosis and enhance muscle growth","volume":"163","author":"Chazaud","year":"2003","journal-title":"J Cell Biol"},{"key":"2025080112522841700_awaf153-B32","doi-asserted-by":"crossref","first-page":"3565127","DOI":"10.1155\/2016\/3565127","article-title":"ROS, cell senescence, and novel molecular mechanisms in aging and age-related diseases","volume":"2016","author":"Davalli","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"2025080112522841700_awaf153-B33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/jcb.10501","article-title":"Interferon-gamma induces reactive oxygen species and endoplasmic reticulum stress at the hepatic apoptosis","volume":"89","author":"Watanabe","year":"2003","journal-title":"J Cell Biochem"},{"key":"2025080112522841700_awaf153-B34","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1124\/jpet.106.107771","article-title":"Busulfan selectively induces cellular senescence but not apoptosis in WI38 fibroblasts via a p53-independent but extracellular signal-regulated kinase-p38 mitogen-activated protein kinase-dependent mechanism","volume":"319","author":"Probin","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"2025080112522841700_awaf153-B35","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/acel.12364","article-title":"Regulation of p53 during senescence in normal human keratinocytes","volume":"14","author":"Kim","year":"2015","journal-title":"Aging Cell"},{"key":"2025080112522841700_awaf153-B36","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/acn3.419","article-title":"Immune and myodegenerative pathomechanisms in inclusion body myositis","volume":"4","author":"Keller","year":"2017","journal-title":"Ann Clin Transl Neurol"},{"key":"2025080112522841700_awaf153-B37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/nan.12384","article-title":"Sporadic inclusion body myositis\u2014A myodegenerative disease or an inflammatory myopathy","volume":"43","author":"Weihl","year":"2017","journal-title":"Neuropathol Appl Neurobiol"},{"key":"2025080112522841700_awaf153-B38","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ajpath.2011.05.055","article-title":"Inclusion body myositis : Laser microdissection reveals differential up-regulation of IFN-g signaling cascade in attacked versus nonattacked myofibers","volume":"179","author":"Ivanidze","year":"2011","journal-title":"Am J Pathol"},{"key":"2025080112522841700_awaf153-B39","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2353\/ajpath.2007.060906","article-title":"Interferon-\u03b3 induces chronic active myocarditis and cardiomyopathy in transgenic mice","volume":"171","author":"Reifenberg","year":"2007","journal-title":"Am J Pathol"},{"key":"2025080112522841700_awaf153-B40","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00401-023-02637-2","article-title":"Senescent fibro-adipogenic progenitors are potential drivers of pathology in inclusion body myositis","volume":"146","author":"Nelke","year":"2023","journal-title":"Acta Neuropathol."},{"key":"2025080112522841700_awaf153-B41","doi-asserted-by":"crossref","first-page":"4761427","DOI":"10.1155\/2019\/4761427","article-title":"Macrophages are key regulators of stem cells during skeletal muscle regeneration and diseases","volume":"2019","author":"Dort","year":"2019","journal-title":"Stem Cells Int"},{"key":"2025080112522841700_awaf153-B42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1084\/jem.194.4.393","article-title":"Selective abrogation of major histocompatibility complex class II expression on extrahematopoietic cells in mice lacking promoter IV of the class II transactivator gene","volume":"194","author":"Waldburger","year":"2001","journal-title":"J Exp Med"},{"key":"2025080112522841700_awaf153-B43","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1089\/jir.2014.0018","article-title":"Transcriptional regulation of important cellular processes in skeletal myogenesis through interferon-\u03b3","volume":"35","author":"Grzelkowska-Kowalczyk","year":"2015","journal-title":"J Interferon Cytokine Res"},{"key":"2025080112522841700_awaf153-B44","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1128\/MCB.05397-11","article-title":"Gamma interferon modulates myogenesis through the major histocompatibility complex class II transactivator, CIITA","volume":"31","author":"Londhe","year":"2011","journal-title":"Mol Cell Biol"},{"key":"2025080112522841700_awaf153-B45","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/nrm3823","article-title":"Cellular senescence: From physiology to pathology","volume":"15","author":"Mu\u00f1oz-Esp\u00edn","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025080112522841700_awaf153-B46","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.18632\/aging.101328","article-title":"TNF\u03b1-senescence initiates a STAT-dependent positive feedback loop, leading to a sustained interferon signature, DNA damage, and cytokine secretion","volume":"9","author":"Kandhaya-Pillai","year":"2017","journal-title":"Aging (Albany NY)."},{"key":"2025080112522841700_awaf153-B47","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: The first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2025080112522841700_awaf153-B48","doi-asserted-by":"crossref","first-page":"719","DOI":"10.2217\/fon.14.272","article-title":"Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis","volume":"11","author":"Yi","year":"2015","journal-title":"Future Oncol"},{"key":"2025080112522841700_awaf153-B49","doi-asserted-by":"crossref","first-page":"5801","DOI":"10.1093\/rheumatology\/keab116","article-title":"JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: A monocentric retrospective study","volume":"60","author":"Le Voyer","year":"2021","journal-title":"Rheumatology."},{"key":"2025080112522841700_awaf153-B50","doi-asserted-by":"crossref","first-page":"152474","DOI":"10.1016\/j.semarthrit.2024.152474","article-title":"Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study","volume":"68","author":"Shan","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025080112522841700_awaf153-B51","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/febs.15182","article-title":"Understanding muscle regenerative decline with aging: New approaches to bring back youthfulness to aged stem cells","volume":"287","author":"Mu\u00f1oz-C\u00e1noves","year":"2020","journal-title":"FEBS J"},{"key":"2025080112522841700_awaf153-B52","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/nm.3655","article-title":"Inhibition of JAK-STAT signaling stimulates adult satellite cell function","volume":"20","author":"Price","year":"2014","journal-title":"Nat Med"},{"key":"2025080112522841700_awaf153-B53","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/nm.3656","article-title":"STAT3 signaling controls satellite cell expansion and skeletal muscle repair","volume":"20","author":"Tierney","year":"2014","journal-title":"Nat Med"},{"key":"2025080112522841700_awaf153-B54","doi-asserted-by":"crossref","first-page":"12480","DOI":"10.1073\/pnas.1516208112","article-title":"Selective targeting of JAK\/STAT signaling is potentiated by bcl-xL blockade in IL-2\u2013dependent adult T-cell leukemia","volume":"112","author":"Zhanga","year":"2015","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2025080112522841700_awaf153-B55","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2665-9913(20)30280-0","article-title":"Sirolimus for treatment of patients with inclusion body myositis: A randomised, double-blind, placebo-controlled, proof-of-concept, phase 2b trial","volume":"3","author":"Benveniste","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2025080112522841700_awaf153-B56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1083\/jcb.200903131","article-title":"Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy","volume":"187","author":"Risson","year":"2009","journal-title":"J Cell Biol"},{"key":"2025080112522841700_awaf153-B57","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1097\/01.TP.0000090752.85709.9F","article-title":"Sirolimus myopathy","volume":"76","author":"Finsterer","year":"2003","journal-title":"Transplantation"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf153\/63025934\/awaf153.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/8\/2883\/63025934\/awaf153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/148\/8\/2883\/63025934\/awaf153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T16:52:41Z","timestamp":1754067161000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/148\/8\/2883\/8121583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":57,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4,29]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf153","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,29]]}}}